Health News Archive - March 13, 2009
A study published today online in The Lancet (March 13, 2009) presented two year data for the bioabsorbable everolimus coronary stent.
KALAMAZOO, Mich., March 13 /PRNewswire-FirstCall/ -- Stryker Corporation (NYSE: SYK) announced today that it will provide webcast and telephone access to its Annual Shareholder Meeting that will be held: April 29, 2009 - 2:00 p.m.
MIDDLEBURY, Ind., March 13 /PRNewswire/ -- Every year, thousands of US citizens travel to Mexico for cancer treatment, because clinics there offer non-toxic therapies and the cost is much less expensive, says TMD Unlimited, a medical tourism corporation.
KALAMAZOO, Mich., March 13 /PRNewswire-FirstCall/ -- Stryker Corporation (NYSE: SYK) announced that it will host a conference call on Monday, April 20, 2009 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended March 31, 2009, and provide an operational update.
A new study finds that a personâ€™s neck thickness may provide as many clues about their risk of developing heart problems as their waist measurement.
In a study of Australian teens, researchers at Flinders University in Adelaide, South Australia discovered that 95 percent of participants had at least one type of sleep disorder.
Doctors may be able to tailor a specialized form of brain surgery to more closely match the needs of Parkinson patients, according to results from the first large-scale effort to compare the two current target areas of deep brain stimulation surgery, or DBS.
A new study by experts at Britainâ€™s Edinburgh University finds that a weakening of the small arteries in the brain may be responsible for 20 percent of strokes.
THOUSAND OAKS, Calif., March 13 /PRNewswire/ -- Plastic and Reconstructive Surgeon Kouros Azar, M.D. offers his Top 10 Tips to patients to help celebrate National Patient Safety Awareness Week from March 8 to 14, 2009 sponsored by The National Patient Safety Foundation (NPSF) in Massachusetts.
Bacterial resistance to antibiotics is one of medicine's most vexing challenges. In a study described in Nature Chemical Biology, researchers from Albert Einstein College of Medicine of Yeshiva University are developing a new generation of antibiotic compounds that do not provoke bacterial resistance.